Skip to content
Bored Studies
RecruitingPhase 3

Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis

Takeda · NCT07286058

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18+ · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 3
Target enrollment
1182
US sites recruiting
19
Study start
March 11, 2026
Record last updated
September 9, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

Psoriatic arthritis (PsA) is a long-term inflammatory disease that affects the joints and skin.

The purpose of this study is to check how safe zasocitinib is, how well it is tolerated and how well it works in adults with PsA over a longer period of time.

Adults who completed the 1-year (52-week) treatment period in one of the parent studies (TAK-279-PsA-3001 [NCT06671483] or TAK-279-PsA-3002 [NCT06671496]) may be able to join this continuation study (also called long-term extension or LTE study). All participants in this continuation study, will receive zasocitinib (lower or higher dose), once a day (QD).

Each participant can be in this study for approximately 2 years (108 weeks). This includes a treatment period of up to 2 years (104 weeks) and a 1-month (4-week) follow-up period to monitor a participant's health.

Being studied: Zasocitinib

Conditions: Psoriatic Arthritis

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • The participant is aged 18 years or older at the time of signing the informed consent form (ICF). In South Korea, the age requirement for adult participants is >=19 years of age.
  • The participant has completed the 52-week treatment period in one of the parent studies (TAK-279-PsA-3001 or TAK-279-PsA-3002) independent of treatment assignment, and without meeting the criteria for permanent discontinuation of trial intervention defined in the parent studies.
  • The participant must be deemed by the investigator to benefit from continued or newly initiated (that is, for participants randomized to active comparator in parent study TAK-279-PsA-3001) zasocitinib therapy.

Exclusion Criteria

  • Any participant who is deemed by the investigator to be not benefiting from the trial intervention based upon lack of improvement or worsening of their symptoms in the respective parent study.
  • Any participant who met the criteria for permanent discontinuation of trial intervention defined in the parent studies (TAK-279-PsA-3001 or TAK-279-PsA-3002).
  • The participant has developed any disease(s) that might confound the evaluations of benefit of zasocitinib therapy since enrollment in the respective parent study, including but not limited to rheumatoid arthritis, axial spondyloarthritis (this does not include a primary diagnosis of PsA with spondylitis), systemic lupus erythematosus, Lyme disease, gout, or fibromyalgia.
  • The participant has developed evidence of a concomitant comorbid skin condition that, in the opinion of the investigator, would interfere with the study assessments, such as evidence of non-plaque PsO (erythrodermic, pustular, predominately guttate PsO, inverse, or drug-induced PsO).

Recruiting US locations

  • Jeffrey Loomer, MD Arizona Arthritis & Rheumatology Research

    Tucson, AZ 85748

    Site contact: Site Contact · 85748 · loomer.research@azarthritis.com

  • First OC Dermatology Research Inc.

    Fountain Valley, CA 92708

    Site contact: Site Contact · 714-531-2966 · vivian.laquer@firstocdermresearch.com

  • Purushotham & Akther Kotha MD

    La Mesa, CA 91942

    Site contact: Site Contact · roshankotha@gmail.com

  • Triwest Research Associates LLC

    La Mesa, CA 91942

    Site contact: Site Contact · 619-334-4735 · drmabaquiao@triwestresearch.com

  • The Cohen Medical Centers

    Thousand Oaks, CA 91360-3967

    Site contact: Site Contact · 805-904-0982 · drcohen@wmresearch.com

  • Denver Arthritis Clinic - Lowry

    Denver, CO 80230

    Site contact: Site Contact · rantolini@dacdenver.com

  • Direct Helpers Research Center

    Hialeah, FL 33012

    Site contact: Site Contact · 305-828-3555 · don@dhrtrials.com

  • Sweet Hope Research Specialty, Inc, d/b/a Neoclinical Research

    Hialeah, FL 33016

    Site contact: Site Contact · csesin1979@aol.com

  • IRIS Research and Development

    Plantation, FL 33324

    Site contact: Site Contact · 954-476-2338 · drvalenzuela@irisrheumatology.com

  • Klein and Associates, M.D., P.A.

    Hagerstown, MD 21740-6138

    Site contact: Site Contact · 301-791-6680 · ookoye@rheumdocs.com

  • Paramount Medical Research & Consulting, LLC

    Middleburg Heights, OH 44130

    Site contact: Site Contact · 440-826-0742 · idiabmd@gmail.com

  • West Tennessee Research Institute

    Jackson, TN 38305

    Site contact: Site Contact · 731-633-0145 · aresearch@arthritisclinic.org

  • Accurate Clinical Research

    Baytown, TX 77521

    Site contact: Site Contact · 832-705-7839 · snajammd@accurateclinicalresearch.com

  • Novel Research LLC

    Bellaire, TX 77401

    Site contact: Site Contact · 832-400-2262 · wajeeha@novelresearch.net

  • Novel Research | Abigail Neiman - Houston, TX

    Houston, TX 77024

    Site contact: Site Contact · neiman@novelresearch.net

  • Northwest Houston Arthritis Center

    Houston, TX 77090

    Site contact: Site Contact · 832-834-5627 · adnan@novelresearch.net

  • West Texas Clinical Research

    Lubbock, TX 79424

    Site contact: Site Contact · 806-993-1040 · jitendra.vasandani@yahoo.com

  • Southwest Rheumatology Research, LLC

    Mesquite, TX 75150

    Site contact: Site Contact · 972-288-2600 · asinghal@swrr.net

  • Advanced Rheumatology of Houston

    The Woodlands, TX 77382united

    Site contact: Site Contact · 281-766-7886 · tbrionez@gmail.com

Study contacts (from the official record)

  • Takeda Contact · +1-877-825-3327 · medinfoUS@takeda.com
All dermatology studies in Arizona →
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis (NCT07286058) | Bored Studies